Sign in

SENSITISE (Inclusive clinical trials education)

@sensitise-eu.bsky.social
13 followers 8 following 30 posts

ERASMUS+ Cooperation Partnerships funded grant to develop free training and education materials for trialists

PostsRepliesMedia
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 12/01/2026
Shariq et al's scoping review on barriers & facilitators in the recruitment of people with a disability draws on 5 themes Risk v benefit Design & management of recruitment protocol Internal & external validity Consent & ethics Systemic factors #MethodologyMonday pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
Barriers and facilitators to the recruitment of disabled people to clinical trials: a scoping review
Underrepresentation of disabled groups in clinical trials results in an inadequate evidence base for their clinical care, which drives health inequalities. This study aims to review and map the potential barriers and facilitators to the recruitment ...
031
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 22/12/2025
Next up #MethodologyMonday focuses on pregnant women. Sewell et al summarise the scientific, ethical, & legal considerations governing research conducted during pregnancy. They also recommend strategies for overcoming impediments to inclusion and trial conduct. pubmed.ncbi.nlm.nih.gov/35934117/
pubmed.ncbi.nlm.nih.gov
Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials - PubMed
Clinical trials to address the COVID-19 public health emergency have broadly excluded pregnant people from participation, illustrating a long-standing trend of clinical trial exclusion that has led to a clear knowledge gap and unmet need in the treatment and prevention of medical conditions experien …
020
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 08/12/2025
The authors analyse the inclusion of women in cardiovascular trials in #MethodologyMonday. Underrepresentation remains a persistent issue & increasingly so for minority women. The current situation has been shown to lead to > side effects & potentially worse outcomes doi: 10.1016/j.ahjo.2022.100109
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 17/11/2025
This #MethodologyMonday by Mohan & Freedman on persistent under-representation of racial & ethnic minorities in clinical trials. They argue that pursuing representative enrollment throughout clinical development is not only a matter of equity but also of scientific rigour. doi.org/10.1002/cpt....
doi.org
A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access
Current clinical research does not reflect the diversity of patient populations, despite continued recommendations to increase enrollment of under-represented racial and ethnic groups. The ramificati...
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 03/11/2025
This #MethodologyMonday by Booth et al focuses on case studies from three NIHR-funded trials demonstrating how publicly available UK population datasets can be used to identify under-served communities. They reflect on the challenges and future developments. pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
Using publicly available UK datasets to identify recruitment sites to maximise inclusion of under-served groups: three case studies
There is strong evidence that those recruited into studies are not always representative of the population for whom the research is most relevant. Development of the study design and funding decisions are points in the research process where ...
021
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 20/10/2025
A #MethodologyMonday - Raven-Gregg & Shepherd on how methodology studies on attitudes to deferred consent often poorly represent ethnic minority groups. They argue for more equitable research, we need better reporting & greater diversity in research teams & ethics committees. doi.org/10.1186/s130...
doi.org
Exploring the inclusion of under-served groups in trials methodology research: an example from ethnic minority populations’ views on deferred consent - Trials
Background Deferred consent is used to recruit patients in emergency research, when informed consent cannot be obtained prior to enrolment. This model of consent allows studies to recruit larger numbe...
021
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 13/10/2025
An audit at a UK primary care CTU assessed the inclusion of underserved groups in trials in this #MethodologyMonday. The authors conclude that many explicit exclusions may not be strictly necessary & call for more inclusive eligibility criteria & standardised data collection doi.org/10.1186/s130...
doi.org
Inclusion of under-served groups in trials: an audit at a UK primary care clinical trials unit - Trials
Background Clinical trials need to include patients who are representative of the population who may receive the tested interventions in the future. The importance of inclusivity is recognised by ethical and funding bodies and has public support. Appropriate inclusion is required to provide equitable evidence-based healthcare and to comply with ethical principles for research. However, there is little information about the inclusivity of most under-served groups in UK clinical trials. Methods This audit assesses the inclusion of under-served groups in trials run by the Oxford Primary Care Clinical Trials Unit (PC-CTU). We included trials with ethical approval between 2017 and 2023. We checked protocols, patient-facing information and selected data collection tools for information on the under-served groups in the INCLUDE guidance and protected characteristics in the UK Equality Act 2010, to identify explicit exclusions and data collection. Results We included 19 trials. They were in a variety of clinical conditions, testing different types of interventions, both Clinical Trial of an Investigational Medicinal Product (CTIMP) and non-CTIMP. Most were non-commercially funded. We reviewed 21 protocols, 29 Patient Information Sheets/Leaflets and 40 data collection tools. Common exclusions were based on age (19), sex or gender (11), language (8), capacity to consent (14), pregnancy (11), multiple health conditions (10) and severity of illness (17). Trials most often collected data on age (19), sex or gender (15), ethnicity (16), education (11), address (13), mental health conditions (6), who gave consent (19), addiction (6), multiple health conditions (10), severity of illness (17), smoking status (12) and obesity (13). Conclusions Often, exclusions were due to the focusing of the trial for a specific group, such as older people, women, or people being treated for a specific severity of condition. However, many explicit exclusions may not have been essential, may have reduced the inclusivity of the trials and might limit the applicability of the trial’s findings to people to whom the tested interventions might be relevant. These include the exclusion of people aged under 18, people without English language fluency and people without capacity to consent. All trials could have collected more informative data on under-served group status.
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 06/10/2025
Oct #MethodologyMonday focuses on a recent editorial: the usefulness of trial data depends crucially on transparent, consistent reporting of who was actually enrolled, not could have been. Trials will introduce a requirement to address this (01/2026). trialsjournal.biomedcentral.com/articles/10....
trialsjournal.biomedcentral.com
Who is in your trial? Improving the reporting of participant characteristics in trial protocols and results - Trials
Advertisement
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 29/09/2025
The last September #MethodologyMonday includes input from the consortium on improving the inclusion of those with impaired capacity with the dedicated INCLUDE framework. This article outlines the development of this dedicated framework. trialsjournal.biomedcentral.com/articles/10....
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 22/09/2025
In the mixed-methods systematic review carried out by Stokes et al, not only were barriers identified, but also facilitators for the implementation of capacity legislation in care homes. #MethodologyMonday pubmed.ncbi.nlm.nih.gov/40370080/
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 15/09/2025
Gréaux et al identified barriers across the health system (cost, training, coordinated service) and wider contributing factors (social stigma or health literacy). Moreover, the solutions proposed dont necessarily address these needs #MethodologyMonday equityhealthj.biomedcentral.com/articles/10....
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 08/09/2025
Bishop et al discuss inclusion of adults with intellectual disabilities in #MethodologyMonday. Findings: non-accessible research design, lack of confidence with capacity & consent, limited resources, & the need for training. onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
The inclusion of adults with intellectual disabilities in health research – challenges, barriers and opportunities: a mixed‐method study among stakeholders in England
Background The study aims to understand system barriers to research participation for people with intellectual disabilities. Methods A mixed-methods approach examined the inclusivity of people wit...
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 01/09/2025
September #MethodologyMonday will focus on the inclusion of persons with disabilities. First, a call to action from Anderson and colleagues for disability inclusion in health research. (not open access) www.nature.com/articles/s41...
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 11/08/2025
In this week's #MethodologyMonday post, Rubagumya et al explore the impact of enrolling patients from lower middle-income countries on the bibliometric output. While many trials include such publics it is not reflected in their bibliometric output. jamanetwork.com/journals/jam...
jamanetwork.com
Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials
This cross-sectional study examines the inclusion of patients with cancer from lower and upper middle–income countries in randomized clinical trials conducted by high-income countries.
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 21/07/2025
The Digital Cancer Research and Vocal co-developed this week’s #MethodologyMonday guidance with patients. They came up with 5 principles for the development of technology clinical trials and an accompanying checklist. christie.openrepository.com/bitstream/ha...
christie.openrepository.com
020
Reposted by SENSITISE (Inclusive clinical trials education)
HRB - Clinical Research Facility - UCC @crf-ucc.bsky.social · 16/07/2025
A fantastic article in today's Irish Examiner by our Director of Education, Prof. Frances Shiely, highlighting the need for more Inclusive Clinical Research and the great work being done by the SENSITISE (@sensitise-eu.bsky.social). Be sure to have a read: www.irishexaminer.com/opinion/comm...
irishexaminer.com
Why medical research needs to be more inclusive — and what we’re doing about it
A new campaign at UCC aims to make health research more inclusive, to include under-served groups like women, ethnic minorities, LGBTQ+ individuals, older adults, and people with disabilities
012
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 15/07/2025
Direct from our consortium, an article on the development of the STEP UP guidance to help researchers design inclusive clinical trials. Learn more about the Strategies for Trialists to promote Equal Participation in clinical trials for Under-served Populations. link.springer.com/article/10.1...
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 07/07/2025
In this hashtag#MethodologyMonday, Chokkara et al. look at the recruitment of underrepresented populations in COVID-19 studies conducted in the US and found: they exclude people with high-risk chronic conditions & trials excluded children, pregnant & lactating women link.springer.com/article/10.1...
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
011
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 30/06/2025
#MethodologyMonday: a call to action from Reza and colleagues for the inclusion of all populations impacted by heart failure with reduced ejection fraction in clinical trials. They also catalogue barriers & propose strategies to ⬆️ inclusivity in future trials. academic.oup.com/eurheartjsup...
academic.oup.com
Representation matters: a call for inclusivity and equity in heart failure clinical trials
Abstract. The burden of heart failure remains substantial worldwide, and heart failure with reduced ejection fraction (HFrEF) affects approximately half of
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 23/06/2025
Daho et al demonstrate through a systematic review of European cancer trials, that a large majority exclude populations with psychiatric & neurological disorders. Often citing compliance concerns & understanding of informed consent. #MethodologyMonday onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com
Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols
Background Cancer clinical trials often employ exclusion criteria that can impact vulnerable populations, particularly individuals with psychological, psychiatric, or neurological conditions. Aims...
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 16/06/2025
For #MethodologyMonday, we revisit the impact of exclusion criteria on sex and race. Stanton et al investigated the potential impact that common exclusion criteria by race and sex have on trial eligibility of patients with ischemic stroke. www.ahajournals.org/doi/full/10....
ahajournals.org
Clinical Trial Exclusion Criteria Affect Trial Inclusivity by Race and Sex | Journal of the American Heart Association
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 10/06/2025
Another #MethodologyMonday on DCTs. Khozin & Coravos highlight the considerations to ensure that decentralised aspects lead to safe & valid research: data protection & cybersecurity, but also limitations linked to technical validation of tools & their durability www.researchgate.net/publication/...
researchgate.net
(PDF) Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical Investigations
PDF | On Apr 23, 2019, Sean Khozin and others published Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical Investigations | Find, read and cite all the research you nee...
000
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 02/06/2025
How is diversity integrated into decentralised clinical trials? The authors list 2 key areas linked to participant selection that should be prioritised for #MethodologyMonday. Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups. doi.org/10.1186/s129...
doi.org
Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups - BMC Medical Ethics
Background The importance of more diversity of study populations in clinical trials is currently widely acknowledged. Decentralized clinical trial (DCT) approaches are presented as a potential means to broaden diversity by eliminating several barriers to participation. However, the precise meaning of, and objectives related to diversity in DCTs remain unclear. Diversity runs the risk of becoming a ‘buzzword’: widely acknowledged to be important, yet prone to multiple interpretations and challenging to implement in practice. We argue that the aim of increasing diversity in clinical trials requires clear and well-substantiated specifications. Methods We analyze the concept of diversity and the ethical requirements surrounding fair participant selection within the context of clinical research, in order to further specify and operationalize the aim of increasing diversity in the context of DCTs. Results Through analyzing the concept of diversity and ethical requirements for fair participant selection, we propose that diversity should be specified in a way that improves the position of the groups that are currently most underrepresented in the research context. In practice, this entails that, in order to contribute to diversity, the selection of participants should prioritize (i) gaining scientific knowledge on groups for which this is lacking, and (ii) inclusion of underrepresented groups in research when appropriate considering a study’s objectives, and risks and benefits. Conclusions Our analysis facilitates translating the aim of increasing diversity with DCTs to more specific and actionable objectives for recruitment and inclusion. Moreover, it contributes to a further specification of the concept of diversity and fair participant selection in research contexts.
012
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 26/05/2025
For #MethodologyMonday we focus on this rapid communication on the impact linked to common exclusion criteria by race and sex on trial eligibility of patients with ischemic stroke in the USA. Stanton et al. (2024) doi.org/10.1161/JAHA...
doi.org
Clinical Trial Exclusion Criteria Affect Trial Inclusivity by Race and Sex | Journal of the American Heart Association
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 19/05/2025
For #MethodologyMonday, let’s increase our vision: Do we consider the diverse representation in PPI? This study led by Shoba Dawson which looks at the involvement of patient and public involvement contributors who are from black and minority ethnic groups. onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com
Black and minority ethnic group involvement in health and social care research: A systematic review
Background Patient and public involvement (PPI) in research is growing internationally, but little is known about black and minority ethnic (BME) involvement and the factors influencing their involv...
020
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 13/05/2025
Dweidar et al discuss the lack of health equity in the development of guidelines. #MethodologyMonday looks at the consequences of guidelines on the population most affected, the challenges & solutions for health equity in real-world experiences. onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com
Advancing health equity: Why guideline development must prioritize fairness and justice
Health equity should be regarded as a fundamental principle and a priority for all guideline development organizations. Yet, this principle has not been consistently prioritized in the creation of ma...
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 05/05/2025
To kick off #MethodologyMonday in May, we bring you a poignant article by the Editors in Chief of the Journal of Clinical Epidemiology. They address the “elephant in the room”, the upheaval of the global evidence research eco-systems pursued by the US administration. www.jclinepi.com/article/S089...
175
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 28/04/2025
Actionable steps to promote diversity and inclusivity in trials were developed during a multi-stakeholder conference. Three tables are presented detailing the steps in this publication. Kelsey, Patrick-Lake, Abdulai, et al. pubmed.ncbi.nlm.nih.gov/35364292
pubmed.ncbi.nlm.nih.gov
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change - PubMed
Improving diversity in clinical trials is an ethical and scientific imperative, which requires a multifaceted approach.
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 21/04/2025
This literature review identified strategies to enhance the racial & ethnic diversity of breast cancer trial populations. It resulted in 8 key strategic themes, which were used to create a new Racial and Minority Growth model. #MethodologyMonday Scott & Westwell orca.cardiff.ac.uk/id/eprint/17...
orca.cardiff.ac.uk
011
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 14/04/2025
#MethodologyMonday scoping review to identify evidence of published good practices in health & social care research priority-setting activities, including people from ethnic minority backgrounds. Only 47 studies from 12 countries are included Ekezie, Cassambai, Curtis et al doi.org/10.1007/s406...
doi.org
Global Insights on the Involvement of Ethnic Minority Populations in Health and Social Care Research Priority Setting: A Systematic Scoping Review - Journal of Racial and Ethnic Health Disparities
Background Representing all population groups in health and social care research is essential for generating research relevant to decision making in everyday clinical and social healthcare policy and ...
010
SENSITISE (Inclusive clinical trials education) @sensitise-eu.bsky.social · 07/04/2025
The article for this #MethodologyMonday looked not only at the specific disease (myalgic encephalomyelitis) but the confounding effect of being from an underserved population. It closes with a call for funding, training and greater research. Bolton, Chew-Graham & van Marwijk doi.org/10.1111/hex....
doi.org
Under‐Served Groups and Myalgic Encephalomyelitis Research Workshop; Multiple Barriers to Effective Healthcare, Research and Public Participation
Public involvement in research and other initiatives for myalgic encephalomyelitis (ME) (also known as chronic fatigue syndrome) has been crucial in raising awareness of the disease and exposing inad...
000